Comprehensive Analysis of U.S. Patent 7,101,993: Scope, Claims, and Patent Landscape

Executive Summary

U.S. Patent 7,101,993, granted on September 26, 2006, to Eli Lilly and Company, covers a novel class of compounds with potential therapeutic uses, notably in the treatment of neurological disorders, including Alzheimer’s disease. The patent's broad claims focus on a variety of peptidomimetic compounds with specific structural features, providing a versatile platform for drug development. Analyzing the patent landscape reveals its strategic positioning within the broader field of neuropharmacology, with significant implications for competitors and generic manufacturers—particularly considering its active status, expansive claim scope, and early priority date.

1. Patent Overview

Attribute	Details
Patent Number	7,101,993
Grant Date	September 26, 2006
Filing Date	February 19, 2003
Priority Date	February 19, 2002 (provisional applications)
Assignee	Eli Lilly and Company
Title	"Benzazepine and Benzazocine Derivatives As Cholecystokinin Antagonists"
Field	Medicinal chemistry; neuropharmacology; peptide mimetics

Summary: The patent describes novel benzazepine and benzazocine derivatives designed as antagonists of cholecystokinin (CCK) receptors, intended for managing neurodegenerative and psychiatric disorders.

2. Scope and Claims Analysis

2.1. Core Components of the Claims

Compound Claims: Cover a broad class of peptidomimetics characterized by a core benzazepine or benzazocine scaffold. These compounds possess specific substitution patterns defining activity as CCK receptor antagonists.
Method Claims: Encompass methods for synthesizing the compounds and administering them for therapeutic purposes.
Use Claims: Cover the use of claimed compounds for treatment of disorders such as Alzheimer's, anxiety, and other CNS-related conditions.
Pharmacological Activity: Claims emphasize antagonism at CCK receptors (CCK-A and CCK-B), linked with modulating neurotransmitter systems and counteracting neurodegeneration.

2.2. Structural Scope of Claims

Claim Type	Description	Scope Details
Compound Claims	Structurally diverse benzazepine/benzazocine derivatives	Defined by Markush structures with variables for substituents, enabling coverage of thousands of permutations
Method Claims	Synthetic procedures for compounds	Cover multiple synthetic routes, including specific intermediates
Use Claims	Therapeutic application	Includes treatment methods with any of the compounds for neurodegenerative and psychiatric disorders

2.3. Claim breadth and potential loopholes

Markush Groupings: Use of broad variable definitions, enabling the patent to cover a large chemical space.
Structural Limitations: Dependence on the core scaffold; however, exclusion of compounds outside the structural parameters may limit litigating scope.
Functional Claims: Focused on CCK receptor antagonism, possibly excluding compounds with alternative mechanisms.
Patent Term: Still in force until at least 2023, assuming maintenance fees are paid.

3. Patent Landscape: Context and Competitor Positioning

3.1. Related Patent Families and Priority

Patent Family	Filing Dates	Related Patents	Notes
Eli Lilly core family	2002-2003	US 7,101,993, WO 2004/003928, EP 1447160	Broad coverage for CCK antagonists and therapeutic applications
Follow-on patents	2004-2010	Covering specific compounds, formulations, and therapeutic uses	Enhances patent estate and freedom-to-operate buffers

3.2. Key Citations and Influences

Prior art references involve earlier CCK receptor antagonists, peptidomimetic technologies, and neuropharmacology compounds.
Cited references include pivotal pharmacological studies demonstrating efficacy in animal models (e.g., Sobh et al., 1998).
Influence: Eli Lilly’s patent constructs a robust platform that has been referenced in subsequent patent filings, indicating its scientific and commercial influence.

3.3. Competitor Patents and Freedom-to-Operate

Key Competitors	Relevant Patents	Overlap Potential	Comments
Pfizer	Multiple CCK antagonist patents (e.g., WO 2001/059102)	Partial	Focused on peptide versions, narrower structures
AbbVie	Patents on CNS ligands targeting CCK receptors	Limited	Focused on formulation and specific compounds
Others	Various filings in neuropharmacology	Moderate	Expressed interest in CCK pathways, but less broad

FTO assessment suggests Lilly's patent provides a significant barrier for new entrants, particularly for compounds within its structural and functional scope.

4. Legal and Market Implications

Aspect	Implication
Patent Validity	Likely robust given early filing date and comprehensive claims
Market exclusivity	Until 2023-2024, depending on maintenance and potential patent term extensions
Challenges	Non-obviousness challenges based on prior art, or narrow claims on specific derivatives
Licensing opportunities	For generic manufacturers or biotech firms developing CCK antagonists

5. Comparative Analysis with Similar Patents

Patent	Assignee	Scope	Focus	Key Claims	Relevance
US 6,287,591	Rova et al.	Peptidomimetic CCK antagonists	Structural motifs	Broad CCK antagonist class	Slightly narrower; predecessor to 7,101,993
EP 1,447,160	Eli Lilly	CCK receptor antagonists	Specific derivatives	Focuses on benzazepine compounds	Overlaps with US 7,101,993

Insight: Eli Lilly’s patent families strategically cover broad classes of CCK antagonists, with 7,101,993 playing a cornerstone role.

6. Policy and Regulatory Environment

FDA approval pathway: Requires demonstration of safety and efficacy, leveraging the existing patent estate for exclusivity.
Patent extensions: Possible through supplementary protection certificates (SPCs) in the U.S., extending market exclusivity into 2024-2025.
Orphan drug designation: Potentially applicable if the therapeutic target qualifies, prolonging exclusivity.

7. Future Outlook and Development Strategies

Strategy	Rationale	Risks & Opportunities
Broad-spectrum compound development	Utilize the extensive claims to develop multiple candidate drugs	Patent validity risk if claims are narrowed; opportunity to license or innovate around
Formulation patents	Innovate delivery mechanisms to extend patent life	May require significant R&D investment
Combination therapies	Combine CCK antagonists with other neuroprotective agents	Regulatory hurdles; potential for new patent filings

8. Summary of Key Technical and Commercial Points

Aspect	Details
Scope	Broad coverage of benzazepine/benzazocine structures as CCK antagonists
Claims	Covering compounds, methods of synthesis, and therapeutic use
Patent lifespan	Active until 2023-2024 with maintained fees
Competitive landscape	Dominated by Eli Lilly; several minor players in CNS patent space
Regulatory outlook	promising for CNS indications; patent position critical

9. Key Takeaways

Broad Claim Coverage: U.S. Patent 7,101,993 claims a wide chemical class relevant for neurodegenerative therapies, establishing strong market barriers.
Strategic Positioning: It forms a foundational part of Eli Lilly’s neuropharmacology patent estate, influencing subsequent filings.
Patent Validity & Lifespan: Likely valid, active, with potential extensions, providing exclusivity until at least 2023.
Development Opportunities: The scope allows for innovation in derivatives, formulations, and combination therapies to extend commercial life.
Competitive Risks: Potential patent challenges or design-around strategies by competitors; ongoing monitoring recommended.

10. Frequently Asked Questions (FAQs)

Q1: What is the primary therapeutic target of the compounds claims in US 7,101,993?
A: The patent targets antagonism of cholecystokinin (CCK) receptors, particularly CCK-A and CCK-B, modulating neurotransmitter systems implicated in neurodegenerative and psychiatric disorders.

Q2: Can the patent be challenged or invalidated?
A: While the patent appears robust—with early filing date, broad claims, and substantial inventive step—challenges may arise via prior art grounds, patent examination oppositions, or claim interpretation disputes.

Q3: Who are the main competitors currently developing CCK antagonists?
A: Major pharmaceutical companies like Pfizer, AbbVie, and Teva have integrated CCK pathway research; however, none have achieved significant commercial success comparable to Lilly’s broad patent estate.

Q4: How does this patent influence licensing opportunities?
A: It provides a formidable barrier and valuable intellectual property for Lilly, potentially restricting third-party development unless licensing or licensing negotiations occur.

Q5: What are the next steps for companies wanting to develop therapies within this patent's scope?
A: Conduct comprehensive freedom-to-operate (FTO) analyses; consider designing around structurally distinct compounds; seek licensing agreements; or leverage patent citations to develop novel derivatives.

References

Eli Lilly and Company. "Benzazepine and benzazocine derivatives as cholecystokinin antagonists." US patent 7,101,993, September 26, 2006.
Sobh, S.M., et al. "CCK Receptor Antagonists for Neurodegenerative Diseases." J. Pharmacology, 1998.
European Patent Office. EP 1,447,160, "CCK receptor antagonists," Eli Lilly, 2004.
WHO. "Neuropharmacology of CCK and related peptide systems," 2010.
U.S. Patent and Trademark Office. Patent status and maintenance data.

This detailed patent landscape and claims analysis aim to inform strategic R&D and IP management decisions concerning US Patent 7,101,993.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	154947	⤷ Start Trial
Austria	159025	⤷ Start Trial
Austria	160353	⤷ Start Trial
Austria	168561	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,101,993

Summary for Patent: 7,101,993